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Background: Complete resection of the thymus is considered appropriate for a thymoma resection because any
remaining thymic tissue can lead to local recurrence. However, there are few studies concerning the extent of
thymus resection. Therefore, we conducted a retrospective study to investigate whether recurrence following
thymoma resection correlated to the extent of resection.
Methods: Between 1986 and 2011, a total of 491 patients underwent resection of thymic epithelial tumors with
curative intent. Of those, we excluded patients with an undetermined World Health Organization (WHO) histologic
type, patients with type C thymoma, and patients who underwent incomplete resection (n = 21). The remaining
342 patients were reviewed retrospectively and compared recurrence according to the extent of resection.
Results: Extended thymectomy was performed in 239 patients (69.9%) and limited thymectomy was performed
103 patients (30.1%). In the extended thymectomy group, 29 recurrences occurred, and in the limited thymectomy
group, 10 recurrences occurred.
Comparing rates of freedom from recurrence between two groups, there was no significant statistical difference in
total recurrence (p =0.472) or local recurrence (p =0.798). After matching patients by stage and tumor size, there
was no significant difference in freedom from recurrence between the two groups (p = 0.162). Additionally, after
adjusting for histologic type and MG, there was also no significant difference (p = 0.125) between groups.
Conclusions: No difference in the rate of recurrence was observed in patients following limited thymectomy
compared with extended thymectomy.
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Complete resection of the thymus gland has been widely
supported as part of thymoma resection because intrathy-
mic metastasis or multifocal recurrence of thymoma can
lead to local recurrence [1,2]. For the same reason, the
International Thymic Malignancy Interest Group (ITMIG)
suggests a complete thymectomy for patients without my-
asthenia gravis (MG) and extended thymectomy for pa-
tients with MG [3]. Thus, surgical resection of anything
less than a complete thymectomy is considered inappropri-
ate at this time except in the context of a clinical trial [3].* Correspondence: kychu@yuhs.ac
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unless otherwise stated.However, as detection of smaller thymomas has im-
proved, and minimally invasive techniques are being
more widely applied in thymoma resections, limited
thymectomy is being considered for resections of non-
invasive thymomas.
Furthermore, while many studies have shown that ex-
tended thymectomy is more effective for thymoma with
MG [4,5], there is little evidence that mandates surgeons
perform complete thymectomy for patients without MG.
At our institution, any patient with MG that is man-
aged surgically undergoes extended thymectomy. How-
ever, surgical treatment for patients without MG does
sometimes involve limited thymectomy, depending on
the stage and size of the thymoma as well as the clinical
judgment of the surgeon. This policy has been supported
by the results of a report previously published by our. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in survival between extended thymectomy and limited
thymectomy (thymomectomy).
Following the proposal by ITMIG regarding the appro-
priate extent of resection, we questioned whether the ex-
tent of thymoma resection correlates with a significant
difference in recurrence rates. This retrospective study
was conducted in order to investigate whether the rate
of recurrence is significantly different following thym-
oma resection relative to the extent of Resection.
Methods
Patients and definitions
Between January 1986 and December 2011, a total of
491 consecutive patients underwent surgery for resec-
tion of epithelial tumors of the thymus at our institute.
Exclusions were made for patients with an undetermined
World Health Organization (WHO) histologic type (n =
20), due to the unavailability of specimen slides or a
completely infarcted tumor, patients with type C thym-
oma (n = 76), patients who only underwent an open bi-
opsy or R2 resection (n = 21; R2 resection indicated
macroscopic residual tumor tissue) and patients who
underwent R1 resection (n = 32; R1 resection indicated
microscopic residual tumor tissue). The remaining 342
patients who underwent R0 resection (no residual tumor
tissue) with curative intent were reviewed retrospect-
ively. The reason we included only R0 resection was that
ITMIG recommended freedom-from-recurrence as the
best measurement of clinical outcome for patients only
who have undergone an R0 resection. Of the patients,
239 patients (69.9%) underwent extended thymectomy
and 103 (30.1%) underwent limited thymectomy. The
thymomas were classified into histological types A, AB,
B1, B2 and B3, according to the WHO classification sys-
tem [7]. When a tumor exhibited mixed histologic types,
the tumor was classified using the most histologically ag-
gressive type observed. For example, when the tumor
had both B2 and B3 components, the tumor was classi-
fied as type B3. Tumor stage was classified into I, IIa,
IIb, III, IVa, IVb, following the Masaoka-Koga classifica-
tion system [8]. Recurrence was divided into three cat-
egories (local, regional and distant recurrence) according
to the definition proposed by ITMIG [9]. The Institu-
tional Review Board of Yonsei University College of
Medicine approved this retrospective study. The need
for individual consent of patients whose records were
evaluated was waived because individuals were not iden-
tified in the study.
Surgery
Extended thymectomy was defined as removal of the
contiguous right and left mediastinal pleura, mediastinal
and pericardiophrenic fatty tissues and dissection of theaorta-pulmonary window in addition to complete resec-
tion of the thymus and thymoma [3]. Limited thymec-
tomy was defined as resection of the thymoma with the
surrounding thymus and fatty tissue, leaving residual
thymic tissue. The definition was the same as those used
by Onuki et al. [10]. When limited thymectomy was per-
formed, a “no-touch” technique was used to avoid dis-
ruption of the capsule. While resecting the thymoma,
the tumor was extracted along with surrounding thymus
and fatty tissue, taking care not to rupture the mass and
spill tumor contents.
Adjuvant therapy
Our strategies for adjuvant therapy were as follows: no
adjuvant therapy for stage I thymomas, radiotherapy for
invasive or incompletely resected thymomas, and chemo-
therapy (with or without radiotherapy) for Masaoka stage
IV thymomas. However, because this strategy was not
standardized for the entire study period, the strategy for
adjuvant therapy was patient-specific according to each
surgeon’s preference.
Adjuvant chemotherapy was generally performed ac-
cording to the ADOC regimen (doxorubicin, cisplatin,
vincristine, and cyclophosphamide) for a total of 6 cycles
every 3–4 weeks. Radiotherapy was applied at the me-
dian dose of 5,040 cGy (180 cGy/fraction, range, 4500 to
6300 cGy) for 5–6 weeks.
Follow up
All patients were followed up at the outpatient clinic at
3- or 6-month intervals, depending on stage, for two
years, and then yearly for the following 3 years or more,
at the discretion of the surgeon. A physical examination
and chest radiograph were performed upon each visit to
the outpatient clinic. Computed tomography (CT) scan
of the chest was obtained at 6-month intervals for the
first 2 years and yearly for the following 3 years or more.
Patients were also followed at neurology or oncology
clinics as needed for further medical management. For
nine patients who did not attend follow-up appointments,
data was obtained by direct telephone contact. Follow-up
for this study was complete up to August 2012.
Statistical analysis
This study was designed with statisticians in order to
compare the difference of recurrence between extended
thymectomy group and limited thymectomy group among
our patients.
Because stage and tumor size could influence the deci-
sion of extent of resection, we matched stage and tumor
size (±0.5 cm). In addition, because the presence of MG
or histologic type could influence the recurrence after
resection, freedom from recurrence was calculated after
adjusting for the influence of MG and histologic type
Table 1 Clinical and surgical characteristics of patients
Variables
Extended
thymectomy
Limited
thymectomy P value
(n = 239) (n = 103)
Age, mean ± SD 45.4 ± 12.10 49.7 ± 13.69 0.005
Sex 0.196
Male 123 (51.5) 61 (59.2)
Female 116 (48.5) 42 (40.8)
MG < 0.0001
No 53 (22.2) 92 (89.3)
Yes 186 (77.8) 11 (10.7)a
WHO histologic type < 0.0001
A 8 (3.3) 15 (14.6)
AB 36 (15.1) 42 (40.8)
B1 44 (18.4) 14 (13.6)
B2 59 (24.7) 19 (18.4)
B3 92 (38.5) 13 (12.6)
Operative approach < 0.0001
Median sternotomy 167 (69.9) 11 (10.7)
Thoracotomy 13 (5.4) 32 (31.1)
VATS 55 (23.0) 55 (53.4)
Clamshell 4 (1.7) -
Cervicotomy - 2 (1.9)
Robotic - 3 (2.9)
Tumor size, mean ± SD 5.7 ± 3.13 6.9 ± 2.95 0.001
Masaoka –Koga stage 0.005
I 110 (46.0) 66 (64.1)
IIa 50 (20.9) 21 (20.4)
IIb 33 (13.8) 12 (11.7)
III 34 (14.2) 4 (3.9)
IVa 10 (4.2) -
IVb 2 (0.8) -
Adjuvant therapy < 0.0001
None 113 (47.3) 79 (76.7)
Radiotherapy 96 (40.2) 22 (21.4)
Chemotherary 6 (2.5) 0 (0.0)
Chemoradiation 24 (10.0) 2 (1.9)
Follow-up time, mean ± SD 79.6 ± 59.49 81.2 ± 65.23 0.830
apost-thymectomy myasthenia gravis.
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was performed after the extent of resection, the presence
of MG and histologic type were set as covariates.
An exact 1:1 matching analysis was performed to get a
well-balanced comparison using the GREEDY algorithm
and a macro developed by Kosanke and Bergstralh [11].
The statistician carried out the matching process using
SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
Before matching, Comparative analyses to identify differ-
ences in patient and tumor characteristics were performed
using the χ2 test of Fisher’s exact test to analyze categorical
variables, and independent t-test to analyze for continuous
variables. After matching, comparative analyses were per-
formed using McNemar test to analyze categorical vari-
ables, and paired t-test to analyze for continuous variables.
Freedom from recurrence was calculated using the
Kaplan-Meier method, and statistical differences in re-
currence were determined using the log-rank test. Re-
currences of thymoma were considered as events. All
deaths without recurrence were considered as censored
observations. The recurrence-free period following resec-
tion was calculated from the date of resection to the date
of last follow-up or diagnosis of recurrence. A P-value of
less than 0.05 was considered statistically significant. All
statistical analyses except matching analysis were per-
formed using the Statistical Package for Social Science
software version 18.0 for Windows (SPSS Inc. Chicago,
Illinois, USA).
Results
Patients in the extended thymectomy group were signifi-
cantly younger, had a higher incidence of MG, had histo-
logically more aggressive types (B2 or B3), had a higher
proportion of operations requiring median sternotomy,
had smaller tumors, and a more advanced Masaoka-Koga
stage compared to those in the limited thymectomy group
(Table 1).
The median follow up time was 63.0 months (range, 1
to 255 months). The median time to recurrence was
52 months (range, 6 to 234 months). Recurrence was ob-
served in 39 (11.4%) of the 342 patients. The recurrence
rate was 12.1% (29/239) in the extended thymectomy
group and 9.7% (10/103) in the limited thymectomy
group. Regional recurrence was the most common in
both groups. The local recurrence rate including over-
lapped recurrence was 24% and 30% in the extended and
limited thymectomy groups, respectively. Distant recur-
rence was discovered in six patients in the extended
thymectomy group: two lung metastases, one liver, one
abdominal lymph node, one lung + regional + local, and
one bone + regional + local recurrence. The pattern of
recurrence is shown in Figure 1.
Regarding freedom from recurrence, there was no signifi-
cant statistical difference observed between the extendedand limited thymectomy groups, in terms of total recur-
rence (p =0.472) as well as local recurrence (p =0.798)
(Figure 2).
Through exact 1:1 matching, 86 patients were selected
from each group. Despite the matching protocol, the ex-
tended thymectomy group showed a higher incidence of
MG and a more aggressive histologic type (Table 2). After
matching, there was no significant difference in regards
Figure 1 The pattern of recurrence. A. The pattern of recurrence of patients before matching. B. The pattern of recurrence of patients after
matching by stage and tumor size.
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(p= 0.162). Furthermore, after adjusting for the influence of
MG and histologic type using Cox-regression, there was also
no significant difference (p = 0.125) (Figure 3A). Because
there was not one case of local recurrence in the extended
thymectomy group, it is not possible to report a statistical
value for freedom from local recurrence (Figure 3B).
Discussion
With respect to recurrence after thymoma resection,
there was no significant difference observed between re-
currences of the groups in this study. However, our re-
sults do not necessarily mean that limited thymectomy
is appropriate for thymoma resection. There are issues
other than risk of recurrence that should be considered
in order to determine the extent of resection. Neverthe-
less, this study might have a significance in that there
have been few studies comparing recurrence according to
the extent of thymus resection, apart from interpretation
of our result or propriety of our policy for thymoma resec-
tion. Because thymomas are slow growing and relatively
rare, most studies on this subject have been retrospect-
ive, single institution, observational studies that report
results over an extended time period. Thus, although
the National Comprehensive Cancer Network (NCCN)Figure 2 Freedom from recurrence and freedom from local recurrenc
recurrence rates were 95.4%, 82.7% and 71.4% in the extended thymectom
p = 0.472). (B) The 5-, 10- and 15-year freedom from local recurrence rates
100.0%, 97.7% and 86.4% in the limited thymectomy group, p = 0.798).guidelines recommend the proper extent of thymoma
resection as complete excision of the lesion with total
thymectomy [12], these recommendations are based on
lower-level evidence because there have been no properly
controlled prospective studies in this area. Accordingly,
many institutions treat patients according to their own
protocols or using individual surgeon’s clinical experience
and judgment. In particular, the extent of resection of thy-
mus differs at the discretion of the surgeon. According to
Kondo et al. [13], among patients with thymoma and MG,
74.8% (190/259) underwent extended thymectomy, 23.2%
(59/259) underwent total thymectomy (thymothymect-
omy) and 2.0% (5/259) underwent limited thymectomy
(resection of the tumor and a portion of the thymus).
Among patients who had thymoma without MG, 37.7%
(273/770) underwent extended thymectomy, 43.4%
(315/770) underwent total thymectomy and 18.9%
(137/770) underwent limited thymectomy. In our institu-
tion, all patients with MG underwent extended thymec-
tomy except 11 who were diagnosed with MG following
surgery (post-thymectomy MG). Among patients without
MG, 36.6% (53/145) underwent extended thymectomy
and 63.4% (92/145) underwent limited thymectomy.
It is accepted that surgical resection is the treatment
of choice for thymoma and complete resection is thee after thymoma resection. (A) The 5-, 10- and 15-year freedom from
y group, 98.9%, 93.8% and 71.1% in the limited thymectomy group,
were 99.0%, 97.8% and 95.1% in the extended thymectomy group,
Table 2 Clinical and surgical characteristics of patients
after 1:1 exact matching by size and stage of tumor
Variables
Extended
thymectomy
Limited
thymectomy P value
(n = 86) (n = 86)
Age, mean ± SD 45.3 ± 12.14 49.7 ± 13.60 0.027
Sex 0.284
Male 43 (50.0) 51 (59.3)
Female 43 (50.0 35 (40.7)
MG < 0.0001
No 22 (25.6) 76 (88.4)
Yes 64 (74.4) 10 (11.6)a
WHO histologic type 0.001
A 6 (7.0) 12 (14.0)
AB 15 (17.4) 34 (39.5)
B1 20 (23.3) 12 (14.0)
B2 17 (19.8) 17 (19.8)
B3 28 (32.6) 11 (12.8)
Operative approach < 0.0001
Median sternotomy 61 (70.9) 8 (9.3)
Thoracotomy 8 (9.3) 27 (31.4)
VATS 16 (18.6) 47 (54.7)
Clamshell 1 (1.2) -
Cervicotomy - 2 (2.3)
Robotic - 2 (2.3)
Tumor size, mean ± SD 6.4 ± 2.67 6.4 ± 2.67 0.943
Masaoka –Koga stage >0.999
I 51 (59.3) 51 (59.3)
IIa + IIb 31 (36.1) 31 (36.1)
III 4 (4.6) 4 (4.6)
IVa + IVb - -
Adjuvant therapy 0.069
None 50 (58.1) 64 (74.4)
Radiotherapy 30 (34.9) 21 (24.4)
Chemotherary 2 (2.3) 0 (0.0)
Chemoradiation 4 (4.7) 1 (1.2)
Follow-up time, mean ± SD 94.5 ± 65.35 85.6 ± 67.92 0.386
Pattern of recurrence
Local 0 1
Local + regional 0 2
Regional 3 7
Distant 2 0
apost-thymectomy myasthenia gravis.
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implies removal of the tumor along with any adjacent
tissues that appear to be invaded by a thymoma [19], but
does not necessitate complete thymus resection. Thus,our institution strives to perform complete thymoma re-
sections by that definition. Even in limited thymectomy
cases, we avoid tumor spillage by resecting the thymoma
along with the surrounding fatty and thymic tissues,
without exposing the tumor at any point, using the so-
called “no-touch” technique.
Similar to other reports, our data has confirmed that
completeness of resection by the above definition is an
important prognostic factor for recurrence after thymoma
resection [20]. However, contrary to our expectation, the
extent of resection is not significantly correlated with risk
for recurrence. Similar results have been reported in a few
other studies, that there is no difference in prognosis
based on the extent of resection. Nakagawa et al. reported
that there was no difference in survival between patients
undergoing complete thymectomy (n = 71) and those
undergoing thymomectomy (n = 55) [18]. Onuki et al. re-
ported that, compared with complete thymectomy, limited
thymectomy is not inferior for treatment of stage I or II
thymoma in regards to disease-free and overall survival,
post-operative onset of MG, and the incidence of multiple
lesions [10]. Sakamaki et al. reported that limited thymec-
tomy by a unilateral thoracoscopic approach was associ-
ated with better short-term outcomes than extended
thymectomy by infrasternal mediastinal approach [11]. In
that series, they also reported that no recurrence has been
detected within the mean follow-up period of 48 months.
On the contrary, Murakawa et al., reported the results
from a 43-year period of surgical treatment for thymoma
[21], suggesting that extended thymectomy is the pre-
ferred treatment for stage I thymoma. They observed that
4 of 64 patients with stage I thymoma developed recur-
rence, and all patients with recurrence had been managed
with thymomectomy only. Additionally, another report by
that group described three cases of local recurrence out of
162 patients that underwent extended thymectomy. These
three were of advanced stage (III or IVa) thymoma ini-
tially, whereas there were no local recurrences observed in
patients with early stage (I or II) disease [22]. Wang et al.
reported that patients who underwent complete thymec-
tomy (n = 16) had a better survival rate than those who
underwent total tumor resection (n = 18) [23].
Because many of the results reported are conflicting
and come from single-institution retrospective studies
with various lengths of follow-up, it is difficult to con-
clude how recurrence risk is affected by the amount of
thymic tissue permitted to remain during surgery.
Our study, like many previously, is a retrospective study
performed at a single institution over a long period of
time. Thus, our results should be interpreted cautiously,
and it cannot be supported as reflecting strong evidence
on this subject. Even though differences between extended
thymectomy and limited thymectomy were not statisti-
cally significant, the graph after matching demonstrated
Figure 3 Freedom from recurrence and freedom from local recurrence after 1:1 exact matching by size and stage of tumor. (A) The
5-, 10- and 15-year freedom from recurrence rates were 98.7%, 94.2% and 86.6% in the extended thymectomy group, 98.7%, 93.1% and 70.0% in
the limited thymectomy group, p = 0.162; p = 0.125 after adjusting with WHO histologic type and the presence of myasthenia gravis). (B) Freedom
from local recurrence after 1:1 exact matching. There was no local recurrence in the extended thymectomy group. The 10- and 15-year freedom
from recurrence rates were 97.4% and 85.9% in the limited thymectomy group.
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more than ten years of surgery. Moreover, no case of local
recurrence was observed in the extended thymectomy
group after matching. Because recurrence takes a long
time to develop with early-stage thymoma, this difference
is worthy of attention and requires investigation over a
much longer period of time. We expect that prospective
studies will be conducted similar to the one currently on-
going by the Japanese Association for Research on the
Thymus, a clinical trial titled “Phase II Study of Thymo-
mectomy for Thymoma Localized in the Thymus” [24].
Hopefully, studies such as this will help provide clearer
answers to the aforementioned questions.
In order to determine an appropriate extent of resec-
tion, there are several issues to be considered in addition
to risk of recurrence.
First, when limited thymectomy is performed, one issue
is how to guarantee a sufficient margin while achieving
complete resection. Transcapsular perithymic invasion can
be subtle and is often not grossly appreciable by the sur-
geon peri-operatively [25]. Thus, even when resection is
performed to include the surrounding thymus and fatty tis-
sue, it is unclear how much tissue in addition to thymoma
should be resected to ensure complete resection. In many
of these limited thymectomy cases, despite a small and
seemingly well-encapsulated thymoma, there is a concern
of incomplete resection should there be microscopic inva-
sion into the surrounding tissue. Our data suggest, how-
ever, that limited resection and incomplete resection are
not associated. There were eleven patients who were classi-
fied as an R1 resection because the tumor was abutting or
involving the resection margin, even considering their diag-
nosis of early stage thymoma (IIa; n = 10, IIb; n = 1); these
patients were excluded from the present study, and only
R0 resections were included. Among those patients, eightunderwent extended thymectomy by a median sternotomy
approach, two patients had limited thymectomy by thora-
cotomy and one patient had a limited thymectomy by cer-
vicotomy. From these cases, we can infer cautiously that
size and location of the thymoma, as well as the opera-
tive approach used, may be associated with complete-
ness of resection, rather than extent of thymus resection
being an indicator.
Secondly, postoperative MG is also important issue re-
lated to the extent of resection. The rate of postoperative
MG in patients without MG at the time of thymoma re-
section is between 1.0 to 4.6% [26]. In our series, eleven
patients (3.2%) developed MG postoperatively, and each
one had undergone limited thymectomy. From this per-
spective, any amount of remaining thymic tissue following
surgery, or presence of ectopic thymus, can lead to MG
following thymoma resection. However, further studies
will be needed to confirm the hypothesis that completes
resection of thymus can prevent postoperative MG.
Thirdly, multifocal development of thymoma in remnant
thymic tissue is also a concern related to the extent of
thymectomy. Previous studies have reported that multiple
lesions of thymoma were known in 1.0 to 3.1% of all pa-
tients undergoing resection [1,2]. There were no cases of
multifocal thymoma in our patients.
In order to get find answers to these concerns, and
hopefully provide a solution to the questions of the appro-
priate extent of resection of thymoma, well-controlled
prospective studies will be necessary. We expect that, in
the future, international collaborative data may be sup-
ported by ITMIG, and randomized-controlled prospective
studies will provide more defined protocols for the surgi-
cal management of thymomas.
There are limitations in our study. First, we used
matching analysis using stage and tumor size because
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presence of MG is also a key factor that might affect the
surgical procedure. We therefore presume that it would
be rational to perform comparative studies solely in pa-
tients without MG, as proposed by Tseng et al. [27]. At
our medical insitution, however, few patients with early-
stage thymoma without MG have undergone extended
thymectomy. This explains the reason why we failed to
evaluate the patients without MG. Thus, we could not
match the presence of MG. Instead, there was a notable
difference in the presence of MG between the two groups.
We therefore adjusted the presence of MG, a key factor
that might affect the recurrence, for the Cox analysis. Our
statistical methods remain problematic, however, our re-
sults might be of significance in that there are few com-
parative studies about the recurrence depending on the
extent of thymic resection. Second, this study was a retro-
spective study performed at a single institution covering a
long period, thus, the results might be influenced by
intrinsic bias. However, this problem would be in almost
all studies about thymoma because thymoma is slow-
growing, rare tumor. Third, our surveillance might under-
estimate the recurrence rate because not every patient
takes a regular chest CT after more than five years. How-
ever, it would not be problematic to compare between the
two groups because the limitation might be consistently
applied to both groups. This problem is also attributed
that there has been no standard surveillance in thymoma
so far. We expect that international collaborative data and
randomized-controlled prospective studies could provide
a standard surveillance.
Conclusion
In summary, limited thymectomy for thymoma resection
does not show a higher rate of recurrence than extended
thymectomy. However, properly controlled prospective
studies are needed to confirm the validity and reliability
of limited thymectomy for thymoma resection.
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